Adverse Effects

Biomarkers

Bladder Cancer

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Endometrial Cancer

Esophageal Cancer

Gastric Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancer

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Kidney Cancer

Chronic Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Leukemia

Liver Cancer

Lung Cancer

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Follicular Lymphoma

Hodgkin Lymphoma

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Lymphoma

Melanoma

Mesothelioma

Multiple Myeloma

Neuroendocrine Tumors

Non-Small Cell Lung Cancer (NSCLC)

Oncology

Ovarian Cancer

Ovarian Cancer Clincal Consult

Pancreatic Cancer

Pediatric Cancers

Prostate Cancer

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Small Cell Lung Cancer (SCLC)

Surgery

Thoracic Malignancies 

Thyroid Cancer

News

Clinical Topics

Integrative Care

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Clinical Consult

Expert Interviews

Face Off

Medical World News

Morning Rounds

OncView

Podcasts

Readout 360

Satellite Sessions

Training Academy

Year in Review

Conferences

Publications

All Journals

Editorial Board

For Authors

Events

Frontline Forum

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Subscribe

Print Subscription

eNewsletter

Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022. 

On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.

Articles

The FDA has set a Prescription Drug User Fee Act date of April 5, 2024 for nivolumab plus chemotherapy in unresectable or metastatic urothelial carcinoma.

Frontline Nivolumab/Chemo Earns FDA Priority Review in Urothelial Carcinoma

Implementing exercise programs into standard oncology care may help improve quality of life for patients with ovarian cancer.

Exercise May Mitigate Chemo-Induced Peripheral Neuropathy in Ovarian Cancer

Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial.

FDA Grants Orphan Drug Designation to LP-284 in High-Grade B-Cell Lymphoma

Videos

The addition of a TIGIT inhibitor to a checkpoint inhibitor showed numerical improvement but did not show statistical significance in patients with recurrent cervical cancer, according to Ritu Salani, MD.

Lead Investigator of SKYSCRAPER-04 Notes No Statistical Significance in Cervical Cancer

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Twitter

Spotlight

Around the Practice 

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Journal

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Genitourinary Cancer

Gynecologic Cancer

Skin Cancer

1rem

Authors

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics

Mitchell Kamrava, MD

Articles